Literature DB >> 8242315

Colonoscopic surveillance after curative resection for colorectal cancer.

S E Patchett1, H E Mulcahy, D P O'Donoghue.   

Abstract

Colonoscopic surveillance after resection for colorectal cancer has been advocated to improve detection of anastomotic recurrence, and of synchronous and metachronous tumours. The benefit provided by colonoscopy remains unproven, and the best timing of examination is unclear. To determine the value of colonoscopy after curative resection for large bowel cancer, the efficacy of an endoscopic surveillance programme in the early detection of intraluminal bowel recurrence in a series of patients admitted with colorectal cancer was examined. Between April 1983 and December 1988, 132 patients underwent colonoscopy. Eight (6.1 per cent) were found to have intraluminal recurrence without evidence of extraluminal spread. Six of these recurrences were at the site of anastomosis and two represented metachronous tumour development. All of these patients were symptomatic at the time of diagnosis. In 15 patients (11.4 per cent), adenomatous polyps were discovered during the initial endoscopic examination. These results indicate that colonoscopic surveillance will rarely allow early detection of asymptomatic intraluminal bowel recurrence, but is valuable in the detection of synchronous lesions. Frequent surveillance is not justified in the early postoperative years and colonoscopy should probably be confined to a single procedure to exclude synchronous lesions.

Entities:  

Mesh:

Year:  1993        PMID: 8242315     DOI: 10.1002/bjs.1800801038

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Charles J Kahi; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas J Robertson; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-02-12       Impact factor: 10.864

2.  Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance.

Authors:  Hartwig Körner; Kjetil Söreide; Pål J Stokkeland; Jon Arne Söreide
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

3.  Surveillance after curative colon cancer resection: practice patterns of surgical subspecialists.

Authors:  K S Virgo; T P Wade; W E Longo; M A Coplin; A M Vernava; F E Johnson
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

4.  Follow-up in colorectal cancer patients: a cost-benefit analysis.

Authors:  R A Audisio; P Setti-Carraro; M Segala; D Capko; B Andreoni; G Tiberio
Journal:  Ann Surg Oncol       Date:  1996-07       Impact factor: 5.344

5.  Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

Authors:  R A Graham; S Wang; P J Catalano; D G Haller
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

6.  Risk factors for metachronous adenoma in the residual colon of patients undergoing curative surgery for colorectal cancer.

Authors:  Abhilasha Patel; Nigel Williams; Nicholas Parsons; Omar Ali; Francesca Peters; Reesha Ranat; Jasmine Shah; Emma Spector; Ramesh P Arasaradnam
Journal:  Int J Colorectal Dis       Date:  2017-08-21       Impact factor: 2.571

7.  Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study.

Authors:  Harindra Jayasekara; Jeanette C Reece; Daniel D Buchanan; Christophe Rosty; S Ghazaleh Dashti; Driss Ait Ouakrim; Ingrid M Winship; Finlay A Macrae; Alex Boussioutas; Graham G Giles; Dennis J Ahnen; Jan Lowery; Graham Casey; Robert W Haile; Steven Gallinger; Loic Le Marchand; Polly A Newcomb; Noralane M Lindor; John L Hopper; Susan Parry; Mark A Jenkins; Aung Ko Win
Journal:  Int J Cancer       Date:  2016-05-09       Impact factor: 7.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.